Literature DB >> 30425093

Rare, Pathogenic Germline Variants in Fanconi Anemia Genes Increase Risk for Squamous Lung Cancer.

Myvizhi Esai Selvan1,2, Robert J Klein1,2, Zeynep H Gümüş3,2.   

Abstract

PURPOSE: Lung cancer is the leading cause of cancer deaths worldwide, with substantially better prognosis in early-stage as opposed to late-stage disease. Identifying genetic factors for lung squamous cell carcinoma (SqCC) risk will enable their use in risk stratification, and personalized intensive surveillance, early detection, and prevention strategies for high-risk individuals. EXPERIMENTAL
DESIGN: We analyzed whole-exome sequencing datasets of 318 cases and 814 controls (discovery cohort) and then validated our findings in an independent cohort of 444 patients and 3,479 controls (validation cohort), all of European descent. We also combined all the samples from both cohorts, which, after principal component analysis (PCA) and population stratification, included 765 cases and 4,344 controls (combined cohort). We focused on rare, pathogenic variants found in the ClinVar database and used penalized logistic regression to identify genes in which such variants are enriched in cases. All statistical tests were two-sided.
RESULTS: We observed an overall enrichment of rare, deleterious germline variants in Fanconi anemia genes in cases with SqCC [joint analysis odds ratio (OR) = 3.08; P = 1.4e-09; 95% confidence interval (CI), 2.2-4.3]. Consistent with previous studies, BRCA2 in particular exhibited an increased overall burden of rare, deleterious variants (joint OR = 3.2; P = 8.7e-08; 95% CI, 2.1-4.7). More importantly, rare, deleterious germline variants were enriched in Fanconi anemia genes even without the BRCA2 rs11571833 variant that is strongly enriched in lung SqCC cases (joint OR = 2.76; P = 7.0e-04; 95% CI, 1.6-4.7).
CONCLUSIONS: These findings can be used toward the development of a genetic diagnostic test in the clinic to identify SqCC high-risk individuals, who can benefit from personalized programs, improving prognosis. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30425093     DOI: 10.1158/1078-0432.CCR-18-2660

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  12 in total

1.  Rare germline deleterious variants increase susceptibility for lung cancer.

Authors:  Jian Sang; Tongwu Zhang; Jung Kim; Mengying Li; Angela C Pesatori; Dario Consonni; Lei Song; Jia Liu; Wei Zhao; Phuc H Hoang; Dave S Campbell; James Feng; Monica E D'Arcy; Naoise Synnott; Yingxi Chen; Zeni Wu; Bin Zhu; Xiaohong R Yang; Kevin M Brown; Jiyeon Choi; Jianxin Shi; Maria Teresa Landi
Journal:  Hum Mol Genet       Date:  2022-10-10       Impact factor: 5.121

Review 2.  Are polygenic risk scores ready for the cancer clinic?-a perspective.

Authors:  Robert J Klein; Zeynep H Gümüş
Journal:  Transl Lung Cancer Res       Date:  2022-05

3.  Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer.

Authors:  Semanti Mukherjee; Chaitanya Bandlamudi; Matthew D Hellmann; Yelena Kemel; Esther Drill; Hira Rizvi; Kaitlyn Tkachuk; Aliya Khurram; Michael F Walsh; Marjorie G Zauderer; Diana Mandelker; Sabine Topka; Ahmet Zehir; Preethi Srinivasan; Myvizhi Esai Selvan; Maria I Carlo; Karen A Cadoo; Alicia Latham; Jada G Hamilton; Ying L Liu; Steven M Lipkin; Sami Belhadj; Gareth L Bond; Zeynep H Gümüş; Robert J Klein; Marc Ladanyi; David B Solit; Mark E Robson; David R Jones; Mark G Kris; Joseph Vijai; Zsofia K Stadler; Christopher I Amos; Barry S Taylor; Michael F Berger; Charles M Rudin; Kenneth Offit
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-07-01       Impact factor: 4.090

Review 4.  A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.

Authors:  Alisa M Goldstein; Elizabeth M Gillanders; Melissa Rotunno; Rolando Barajas; Mindy Clyne; Elise Hoover; Naoko I Simonds; Tram Kim Lam; Leah E Mechanic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

5.  Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.

Authors:  Taofeek K Owonikoko; Mary W Redman; Lauren A Byers; Fred R Hirsch; Philip C Mack; Lawrence H Schwartz; Jeffrey D Bradley; Thomas E Stinchcombe; Natasha B Leighl; Tareq Al Baghdadi; Primo Lara; Jieling Miao; Karen Kelly; Suresh S Ramalingam; Roy S Herbst; Vassiliki Papadimitrakopoulou; David R Gandara
Journal:  Clin Lung Cancer       Date:  2021-01-10       Impact factor: 4.785

6.  Functional Common and Rare ERBB2 Germline Variants Cooperate in Familial and Sporadic Cancer Susceptibility.

Authors:  Riyue Bao; Anita Ng; Mark Sasaki; Myvizhi Esai Selvan; Alyna Katti; Hyesan Lee; Lei Huang; Andrew D Skol; Cinzia Lavarino; Hector Salvador; Robert J Klein; Zeynep H Gümüş; Jaume Mora; Kenan Onel
Journal:  Cancer Prev Res (Phila)       Date:  2021-01-08

7.  Insights Into the Somatic Mutation Burden of Hepatoblastomas From Brazilian Patients.

Authors:  Talita Ferreira Marques Aguiar; Maria Prates Rivas; Silvia Costa; Mariana Maschietto; Tatiane Rodrigues; Juliana Sobral de Barros; Anne Caroline Barbosa; Renan Valieris; Gustavo R Fernandes; Debora R Bertola; Monica Cypriano; Silvia Regina Caminada de Toledo; Angela Major; Israel Tojal; Maria Lúcia de Pinho Apezzato; Dirce Maria Carraro; Carla Rosenberg; Cecilia Maria Lima da Costa; Isabela W Cunha; Stephen Frederick Sarabia; Dolores-López Terrada; Ana Cristina Victorino Krepischi
Journal:  Front Oncol       Date:  2020-05-05       Impact factor: 6.244

8.  Enrichment of heterozygous germline RECQL4 loss-of-function variants in pediatric osteosarcoma.

Authors:  Kim E Nichols; Chimene A Kesserwan; Jamie L Maciaszek; Ninad Oak; Wenan Chen; Kayla V Hamilton; Rose B McGee; Regina Nuccio; Roya Mostafavi; Stacy Hines-Dowell; Lynn Harrison; Leslie Taylor; Elsie L Gerhardt; Annastasia Ouma; Michael N Edmonson; Aman Patel; Joy Nakitandwe; Alberto S Pappo; Elizabeth M Azzato; Sheila A Shurtleff; David W Ellison; James R Downing; Melissa M Hudson; Leslie L Robison; Victor Santana; Scott Newman; Jinghui Zhang; Zhaoming Wang; Gang Wu
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-10-23

9.  Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk.

Authors:  Myvizhi Esai Selvan; Marjorie G Zauderer; Charles M Rudin; Siân Jones; Semanti Mukherjee; Kenneth Offit; Kenan Onel; Gad Rennert; Victor E Velculescu; Steven M Lipkin; Robert J Klein; Zeynep H Gümüş
Journal:  J Thorac Oncol       Date:  2020-08-28       Impact factor: 15.609

10.  Ancestry-specific predisposing germline variants in cancer.

Authors:  Ninad Oak; Andrew D Cherniack; R Jay Mashl; Fred R Hirsch; Li Ding; Rameen Beroukhim; Zeynep H Gümüş; Sharon E Plon; Kuan-Lin Huang
Journal:  Genome Med       Date:  2020-05-29       Impact factor: 15.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.